Sionna Therapeutics (NASDAQ:SION) Hits New 1-Year High – Here’s What Happened

Sionna Therapeutics, Inc. (NASDAQ:SION) shares hit a new 52-week high during trading on Saturday . The company traded as high as $51.00 and last traded at $49.41, with a volume of 1139291 shares changing hands. The stock had previously closed at $45.29.

Analyst Upgrades and Downgrades

SION has been the topic of several research analyst reports. BTIG Research reissued a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a research report on Wednesday, May 13th. JonesTrading raised their target price on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Citizens Jmp restated a “market outperform” rating and set a $63.00 price target on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Finally, Stifel Nicolaus raised their price objective on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, May 18th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $53.22.

Sionna Therapeutics Stock Performance

The firm has a fifty day moving average of $40.74 and a two-hundred day moving average of $39.61. The company has a market cap of $2.23 billion, a PE ratio of -25.60 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Sell-side analysts expect that Sionna Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Insider Activity at Sionna Therapeutics

In related news, Director Orbimed Advisors Llc sold 85,918 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the sale, the director directly owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the completion of the transaction, the director directly owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 989,630 shares of company stock worth $44,987,483. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors have recently made changes to their positions in the stock. Eventide Asset Management LLC purchased a new position in shares of Sionna Therapeutics in the fourth quarter valued at $26,290,000. Vanguard Group Inc. raised its stake in shares of Sionna Therapeutics by 81.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after purchasing an additional 512,803 shares during the period. State Street Corp lifted its holdings in Sionna Therapeutics by 188.7% during the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after purchasing an additional 453,196 shares in the last quarter. Jennison Associates LLC boosted its stake in Sionna Therapeutics by 30.1% in the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after purchasing an additional 335,942 shares during the period. Finally, Viking Global Investors LP grew its holdings in Sionna Therapeutics by 8.2% during the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after buying an additional 242,427 shares in the last quarter.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.